Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients. Recent insight into the heterogeneous nature of GBM suggests a more personalized approach to treatment may be necessa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Weyhenmeyer, Birgit C., Noonan, Janis, Würstle, Maximilian L., Lincoln, Frank A., Johnston, Grainne, Rehm, Markus, Murphy, Brona M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5308652/
https://ncbi.nlm.nih.gov/pubmed/27494880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10973
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky